VAL 201

Drug Profile

VAL 201

Alternative Names: VAL-201

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Cancer Research Technology
  • Developer ValiRx
  • Class Peptides
  • Mechanism of Action DNA synthesis inhibitors; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer; Solid tumours
  • Preclinical Endometriosis

Most Recent Events

  • 07 Oct 2016 Efficacy and adverse events data from a phase-I/II trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Nov 2014 Biomarkers information updated
  • 01 Oct 2014 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Late-stage disease) in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top